Next up on our introduction to minor cannabinoids, is Cannabidivarin (CBDV). So, what is CBDV cannabinoid?
In simple terms, CBDV is another part of the cannabis plant, a compound found within the genetic make up.
To us at Sanobiotec, CBDV is so much more than just another phytocannabinoid found within the cannabis plant though.
CBDV cannabinoid harbours plenty of powerful potential, especially when it comes to preventing epileptic seizures. It’s always a good idea to be cautious with things like this, so as to not raise expectations unrealistically, but on the other hand, when all the evidence is suggesting that CBDV is incredibly beneficial in the therapeutic prevention and treatment of seizures, it’s hard to not get a little excited.
Structurally and functionally, CBDV cannabinoid is very similar to the major cannabinoid cannabidiol (CBD) but unlike CBD, CBDV is understood to modulate its primary physiological effects independently of the endocannabinoid receptors CB1 and CB2.
It’s much less well known too, and that’s understandable, given the fact that it occurs in much lower percentages than the major cannabinoid it is similar to.
Is CBDV another clever little compound then? We certainly think so.
So, where do we get it from? Where can it be found?
Primarily sourced from Cannabis sativa strains found in Asia and Africa, higher concentrations of CBDV are found in strains of cannabis plant with low THC and higher CBD content.
Typically, higher percentages of THC would be considered to have more ‘trippy’ effects, making strains like this more popular for recreational users. That’s not what we’re talking about here though. We’re looking at the therapeutic benefits of minor cannabinoids.
CBDV’s potential may not be limited to only a few benefits. Further research and development provides the opportunity to explore the benefits of this minor cannabinoid. For a start, the receptor TRPV1 is also known to regulate pain transmission and modulation, which raises the question as to whether CBDV could be used to ameliorate neuropathic pain.
This is quite exciting to Sanobiotec, and so is the fact that preliminary evidence suggests CBDV displays anti-inflammatory effects as it binds to the TRPA1 receptor.